Clinical trials: Neurocognitive Disorder
Hearing Loss, Cognitive Impairment, Mild
ENACT Program on Auditory Perception and Function, Cognitive Function and Health-related Quality of Life
Although previous studies indicated that tackling hearing loss may have a secondary benefit in improving cognitive function and delaying the onset of dementia, a more integrated care approach to optimize both hearing and…
- Trial name
- NCT06955494
- Testing
- Empowerment Network for Auditory-Cognitive Training (ENACT) Program, Usual Care
- Where
- Hong Kong
- Volunteers
- 62 people
- Sponsor
- The University of Hong Kong
Dementia
EFFECT OF FACE-TO-FACE AND VIRTUAL REALITY-BASED SALUTOGENESIS NURSING CARE IN PATIENTS WITH DEMENTIA
The purpose of this clinical study is to examine the effects of nursing care based on the Salutogenesis Model on the sense of coherence (meaningfulness, comprehensibility, and manageability) and quality of life of people living…
- Trial name
- SM-VR-DEMENTIA (NCT07816731)
- Testing
- Face-to-Face Salutogenesis Model-Based Nursing Care, Virtual Reality-Supported Salutogenesis Model-Based Nursing Care
- Where
- Turkey (Türkiye)
- Volunteers
- 73 people
- Sponsor
- TC Erciyes University
Schizophrenia; Psychosis, Cognitive Impairment
A Study Evaluating the Efficacy of Xanomeline/Trospium (XT) on Cognitive Impairment After 24 and 52 Weeks of Treatment in Adult Participants With Schizophrenia
Schizophrenia is a long-lasting and serious mental health disorder that affects about 1% of people worldwide. It can cause symptoms such as hallucinations and delusions (called positive symptoms), confused or disorganized…
- Trial name
- SHINE (NCT07084831)
- Testing
- Xanomeline/trospium
- Where
- 16 sites in Austria, Belgium and 8 more
- Volunteers
- 171 people
- Sponsor
- European Group for Research In Schizophrenia
Huntington Disease
Home-based Transcranial Direct Current Stimulation Open Trial for Behavioral and Cognitive Symptoms in Huntington's Disease
The purpose of this study is to assess feasibility, acceptability, and safety of providing transcranial direct current stimulation( tDCS) to Huntingtons Disease (HD) patients in the early to middle stages and to assess the…
- Trial name
- NCT05326451
- Testing
- active tDCS
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- The University of Texas Health Science Center, Houston
Alzheimer Disease
Playful Multimodal Intervention, Monitoring and Decision Support for Activation of People With Alzheimer's Dementia
The worldwide prevalence of dementia is increasing. Pharmaceutical therapies, at the best, slow the degenerative process, observable in Alzheimer's disease (AD).
- Trial name
- M-AAL (NCT04628702)
- Testing
- tablet training
- Where
- Austria
- Volunteers
- 24 people
- Sponsor
- Medical University of Graz
Alzheimer's Disease
Single Photon Emission Computed Tomography (SPECT) Imaging Study to Develop a Biomarker for Alzheimer's Disease
The main objectives of this proposal are as follows: To assess the dynamic uptake and washout of 123-I MNI-388 and MNI 390, a potential imaging biomarker for β-amyloid burden in brain, using single photon emission computed…
- Trial name
- NCT00886951
- Testing
- I123MNI388/I123MNI390
- Where
- United States
- Volunteers
- 2 people, healthy volunteers welcome
- Sponsor
- Institute for Neurodegenerative Disorders
Parkinson's Disease Dementia
Ambroxol as a Treatment for Parkinson's Disease Dementia
The present study will test the hypothesis that the medication Ambroxol is safe and well tolerated and will improve cognitive and motor symptoms of Parkinson's Disease Dementia (PDD).
- Trial name
- NCT02914366
- Testing
- Ambroxol
- Where
- Canada
- Volunteers
- 55 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
PTSD, Alzheimer Disease
First-In-Human (FIH), Single Ascending Dose (SAD) Study of FluoroEthylNorMemantine (FENM)
The goal of this First-In-Human (FIH) trial is to learn about safety and PharmacoKinetics (PK) in healthy adult volunteers. The main questions it aims to answer are: What is the safety of single ascending doses of the…
- Conditions
- PTSD, Alzheimer Disease, Brain Diseases, Neuro-Degenerative Disease
- Trial name
- NCT05921929
- Testing
- Fluoroethylnormemantine (FENM)
- Where
- Belgium
- Volunteers
- healthy volunteers welcome
- Sponsor
- ReST Therapeutics
Huntington Disease
An Extension of the HORIZON Protocol Evaluating the Safety of Dimebon (Latrepirdine) in Subjects With Huntington Disease
An open-label extension study of the HORIZON protocol evaluating the safety of dimebon (latrepirdine)in subjects with Huntington disease.
- Trial name
- HORIZON PLUS (NCT01085266)
- Testing
- Dimebon (latrepirdine)
- Volunteers
- 362 people
- Sponsor
- Medivation, Inc.
Alzheimer Disease
A Long Term Extension Study Evaluating ACC-001 With QS-21 in Subjects With Mild to Moderate Alzheimer's Disease
The purpose of this study is to assess the long term safety, tolerability, and immunogenicity of ACC-001, an investigational vaccine, plus QS-21 in subjects with mild to moderate Alzheimer's disease.
- Trial name
- NCT00960531
- Testing
- ACC-001+ QS21 (3mcg), ACC-001 (10 mcg) + QS-21, ACC-001+QS-21 (30mcg)
- Where
- 28 sites in United States
- Volunteers
- 160 people
- Sponsor
- Pfizer
Intensive Care Unit Delirium, Cardiac Surgery
Delirium After Cardiac Surgery in Intensive Care Units
STUDY SUMMARY STUDY DESIGN The study will be conducted over twelve months in the Cardiac Intensive Care Unit (ICU) at Hammersmith Hospital, Imperial College Healthcare NHS Trust (ICHT).
- Conditions
- Intensive Care Unit Delirium, Cardiac Surgery, Post Operative Delirium
- Trial name
- DaCsi-ICU (NCT06355570)
- Testing
- Personal Pictures, Family Videos, Family Videos - Intervention as required
- Where
- United Kingdom
- Volunteers
- 30 people
- Sponsor
- Imperial College Healthcare NHS Trust
Dexmedetomidine, Postoperative Delirium
Dexmedetomidine Alleviates Postoperative Delirium After Brain Tumor Resections
Postoperative delirium (POD) is a common complication, and the incidence rate is about 25% in non cardiac surgery. Previous studies have reported that the total incidence of neurological pod ranged from 10% to 22%.
- Trial name
- NCT04674241
- Testing
- Dexmedetomidine, 0.9% saline
- Where
- 2 sites in China
- Volunteers
- 260 people
- Sponsor
- Beijing Tiantan Hospital
Covid19, Neurocognitive Dysfunction
Hyperbaric Oxygen Therapy for Post-COVID-19 Syndrome
Post-COVID-19 syndrome is an assembly of symptoms, following an infection with Coronavirus disease 2019 (COVID-19). The syndrome is characterized by cognitive impairment, fatigue, sleep disorders, smell and taste disorders, pain…
- Trial name
- HBOTpCOVID (NCT04647656)
- Testing
- Hyperbaric oxygen
- Where
- Israel
- Volunteers
- 91 people
- Sponsor
- Assaf-Harofeh Medical Center
Multiple Sclerosis, Cognitive Deficits
Computerized Exercise Training for Cognitive Remediation in Adults With Multiple Sclerosis Treated With Gilenya
This study is investigating the efficacy of computer-based cognitive exercises as a means of cognitive remediation in patients with Multiple Sclerosis (MS) who are beginning the disease modifying pharmacotherapy Gileyna.
- Conditions
- Multiple Sclerosis, Cognitive Deficits, Gilenya Modifying Therapy for MS
- Trial name
- NCT02141022
- Testing
- plasticity-based computerized cognitive remediation program, Gileyna
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Stony Brook University
Magnesium, Emergence Agitation
Effect of Preoperative Oral Magnesium on Emergence Agitation
This prospective randomized controlled study will be conducted to evaluate the effects of preoperative oral magnesium on the incidence and severity of emergence agitation in children undergoing adenotonsillectomy using…
- Conditions
- Magnesium, Emergence Agitation, Adenotonsillectomy
- Trial name
- NCT07082894
- Testing
- Magnesium
- Where
- Egypt
- Volunteers
- 120 people
- Sponsor
- Tanta University
Stroke, Cognitive Impairment
Cognitive Rehabilitation and Galantamine for Post Stroke Cognitive Impairment
The investigators would like to conduct a double blind placebo-controlled prospective study to show the impact of a treatment combining a specific cognitive rehabilitation program and acetylcholinesterase inhibitors on executive…
- Trial name
- COGICRehab (NCT01508494)
- Testing
- Galantamine
- Where
- France
- Volunteers
- 47 people
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Delirium, Intensive Care Unit Delirium
Family-partnered Delirium Prevention, Detection, and Management in the ICU
Almost half of critically ill patients experience delirium. Delirium is associated with impaired cognition, mortality, and increased healthcare costs.
- Conditions
- Delirium, Intensive Care Unit Delirium, Post Intensive Care Unit Syndrome, Post Intensive Care Unit Syndrome Family
- Trial name
- ACTIVATE (NCT07896356)
- Testing
- Standard of Care, Delirium Education, Prevention, and Management
- Where
- Canada
- Volunteers
- 1,344 people
- Sponsor
- University of Calgary
Post-COVID-19 Syndrome
Methylprednisolone in Patients With Cognitive Deficits in Post-COVID-19 Syndrome (PCS)
This clinical trial aims to learn about the therapeutic value of Methylprednisolone, a well-known immunosuppressant, on cognitive deficits in patients with post-COVID-19 syndrome (PCS).
- Trial name
- NCT05986422
- Testing
- Methylprednisolone
- Where
- Germany
- Volunteers
- 96 people
- Sponsor
- Charite University, Berlin, Germany
Delirium on Emergence
Efficacy of Dexmedetomidine Versus Clonidine to Control Delirium in Patients Undergoing CABG
This prospective, randomised, double blinded, controlled clinical trial will be conducted in 147 patients between 60 yr and 70 yr , ASA physical status II and III, undergoing CABG.
- Trial name
- NCT03477994
- Testing
- Dexmedetomidine, Clonidine
- Where
- Egypt
- Volunteers
- 147 people
- Sponsor
- Ain Shams University
Suspected Delirium After Elective or Emergency Heart Surgery, CAM-ICU Diagnosed Delirium
Evaluation if Physostigmine Reduces Symptoms in Patients Who Has Developed a Delirium in Intensive Care After a Surgery
Evaluation if physostigmine reduces symptoms in patients who has developed a delirium in Intensive care after a surgery
- Trial name
- NCT02216266
- Testing
- Physostigmine, Sodium Chloride solution
- Where
- Germany
- Volunteers
- 120 people
- Sponsor
- PD Dr. Bertram Scheller